Intelligence · Clinical Development
Pipeline search results
Programs matching “neoadjuvant” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 27 pipeline programs matching "neoadjuvant" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Adjuvant chemotherapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Total Neoadjuvant Treatment
1 trial -
Datopotamab deruxtecan for Stage I-III Triple-negative Bre…
AstraZeneca AB
Stage I-III Triple-negative Breast Cancer with residual invasive disease after neoadjuvant systemic therapy.
1 trial -
HIPEC with neoadjuvant chemotherapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Gastric Cancer
1 trial -
PEMBROLIZUMAB
Ningbo Cancer Hospital
Patient with early triple-negative breast cancer (TNBC) achieving pathologic complete response (pCR) after neoadjuvant systemic chemotherapy and pembrolizumab.
1 trial -
Tislelizumab（neoadjuvant）
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Head and Neck Squamous Cell Carcinomas
1 trial -
neoadjuvant chemotherapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Epithelial Ovarian Cancer
1 trial -
ASND0029
Lacuna Pharma Pty Ltd
Locally advanced or metastatic solid tumor malignancies, platinum resistant ovarian cancer, post-anti-pd-1 melanoma, second line or later cervical cancer, neoadjuvant melanoma and neoadjuvant non-small cell lung cancer, post-anti-pd-L1 non-small cell lung cancer, post-anti-pd-L1 small cell lung cancer, second line or later HER2+ breast cancer
1 trial -
Apatinib
The First People's Hospital of Lianyungang
Systematic Review of the pCR Rate of Apatinib Combined With Albumin Paclitaxel and Carboplatin Regimen for Neoadjuvant Therapy of Triple-negative Breast Cancer
1 trial -
ELACESTRANT
Fondazione Telethon ETS
Patients with HR-positive, HER2-negative, non-metastatic node positive BC eligible for neoadjuvant treatment (clinical stage II-III)
1 trial -
Fibromun, Darleukin
Philogen S.p.A.
Phase II, open label, multicentric, proof-of-principle basket trial in patients with malignant tumors of the skin amenable to intratumoral injection, and in a curative or neoadjuvant or palliative intention, including: • Basal cell carcinoma (BCC) • Cutaneous squamous cell carcinoma (cSCC) • Merkel cell carcinoma (MCC) • Keratoacanthoma (KA) • Malignant adnexal tumors of the skin (MATS) • Tumors from cutaneous T-cell lymphoma (CTCL) • Kaposi’s sarcoma (KS)
1 trial -
Neoadjuvant Chemotherapy
Xiangya Hospital of Central South University
High-Grade Upper Tract Urothelial Carcinoma
1 trial -
Neoadjuvant Chemotherapy (NACT)
The First People's Hospital of Lianyungang
HR+/HER2- Breast Cancer
1 trial -
Neoadjuvant Chemotherapy combined with Neoadjuvant Radiotherapy
The First People's Hospital of Lianyungang
Breast Cancer
1 trial -
Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Lung Cancer (NSCLC)
1 trial -
Neoadjuvant Therapy
The First People's Hospital of Lianyungang
Gastric Cancer
1 trial -
Neoadjuvant therapy: TCbHPy
The First People's Hospital of Lianyungang
Breast Cancer
1 trial -
RC48- ADC
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cance
1 trial -
Toripalimab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Neoadjuvant Therapy
1 trial -
Total Neoadjuvant Treatment
The First People's Hospital of Lianyungang
Biliary Tract Neoplasms
1 trial -
UC-BCG-2211, CAPPA
Ningbo Cancer Hospital
Triple Negative Breast Cancer with residual disease after neoadjuvant chemo-immunotherapy.
1 trial -
Verzenios 50 mg film-coated tablets
Ningbo Cancer Hospital
High/intermediate risk hormone receptor (HR) positive/human epidermal growth factor receptor 2 (HER2) negative breast cancer patients with indication of neoadjuvant therapy.
1 trial -
cadonilizumab combined with neoadjuvant radiochemotherapy
The First People's Hospital of Lianyungang
Esophageal Squamous Cell Carcinoma
1 trial -
neoadjuvant anti-PD-1
Shanghai Chest Hospital
Esophageal Cancer
1 trial -
pyrotinib and trastuzumab in combinition with neoadjuvant chemotherapy
The First People's Hospital of Lianyungang
HER2-positive Breast Cancer
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.